The correct pairing is Herpes simplex type I and herpes encephalitis.

Herpes simplex virus type I is known to cause herpes encephalitis, which is a rare but serious infection of the brain. This condition can lead to inflammation of the brain, seizures, and even death if not treated promptly.

The other pairings are incorrect because they do not match the specific viruses with the corresponding diseases. For example, Human herpesvirus type 7 is not associated with Kaposi’s Sarcoma, and Human herpesvirus type 8 is not associated with Roseola infantum. It is important to correctly match the virus with the disease in order to understand the causes and treatments for each condition.

Antibiotic resistance can occur through various mechanisms, including the inactivation of the drug by enzymes produced by the bacteria. These enzymes can modify or degrade the antibiotic, rendering it ineffective in killing the bacteria.

Transduction is a process where naked DNA is transferred from one bacterium to another through a virus, potentially transferring resistance genes along with it.

Active expulsion of the drug by nuclear efflux systems is another way bacteria can develop resistance. These efflux pumps can pump out the antibiotic before it can have an effect on the bacteria.

Transformation is a process where bacteria can acquire resistance genes from their environment, such as from other bacteria. This transfer of resistance genes can lead to the development of antibiotic resistance in the bacteria.

Therefore, the correct answer is: By enzymes which inactivate the drug, By transduction when naked DNA is incorporated by the host DNA, By active expulsion of drug by nuclear efflux systems, and By transformation when resistance is transferred from 1 bacteria to another.

The 2023 Guideline for the Prevention of Vertical Transmission of Communicable Infections emphasizes the importance of proper documentation for managing records of HIV-positive women and their infants. The recommended documents for this purpose are The Maternity Case Record for the mother and The Road to Health Booklet for the HIV-exposed infant.

The Maternity Case Record is a comprehensive document that tracks the mother’s health care and treatment practices throughout her pregnancy, delivery, and postpartum period. It includes information on prenatal care, HIV testing and treatment, delivery details, and postpartum follow-up. By using this record, healthcare providers can ensure that the mother receives appropriate care and that her HIV status is properly managed.

The Road to Health Booklet is a similar document designed for infants, including those who are exposed to HIV. It tracks the infant’s growth, development, and immunization status, as well as any HIV testing and treatment they may require. By using this booklet, healthcare providers can monitor the infant’s health and ensure they receive the necessary care to prevent vertical transmission of HIV.

Overall, using these recommended documents allows for comprehensive and systematic tracking of health care and treatment practices for HIV-positive women and their infants, ultimately helping to prevent vertical transmission of HIV and improve health outcomes for both mother and child.

During ART initiation counseling, the healthcare provider typically emphasizes key messages to the patient to ensure successful adherence to their medication regimen. These messages include the risks of poor adherence, the importance of viral load suppression, strategies for missed doses, and methods for storing medication safely.

The frequency of clinic visits is not typically emphasized as a key adherence message during counseling. While it is important for patients to attend their clinic visits regularly for monitoring and support, it is not typically highlighted as a key message during counseling. Instead, the focus is on ensuring that the patient understands the importance of adherence to their medication regimen and has the necessary tools and knowledge to adhere to their treatment plan effectively.

Enhanced Adherence Counselling (EAC) is a specialized form of counseling aimed at individuals who are struggling with adhering to their treatment regimen, particularly in the context of HIV/AIDS treatment. The purpose of EAC, as outlined in the guidelines, is to address issues with adherence to treatment and develop strategies to overcome barriers that may be hindering the individual’s ability to consistently take their medication as prescribed.

The options provided in the question highlight the importance of EAC in providing education, support, and guidance to individuals who may be experiencing challenges with adherence. While EAC does involve educating clients about the side effects of antiretroviral therapy (ART) and monitoring viral load, its primary focus is on addressing adherence issues and developing strategies to improve treatment adherence.

In this case, the most appropriate investigation to make a diagnosis of active tuberculosis is sputum for acid-fast bacilli smear. This test involves collecting three-morning sputum samples and testing them for the presence of acid-fast bacilli using gram staining. This test is quick, provides fast results, and allows for prompt initiation of treatment if tuberculosis is confirmed.

Blood culture, on the other hand, would be less sensitive than sputum testing for diagnosing active tuberculosis. A chest X-ray would not be able to differentiate between active tuberculosis and old infection. The Mantoux test may be positive in cases of previous infection or vaccination against tuberculosis, but it does not confirm active disease. A CT chest would also not be able to differentiate between active infection and old tuberculosis findings.

Therefore, in this scenario, sputum for acid-fast bacilli smear is the most appropriate investigation to diagnose active tuberculosis.

In this case, the patient presented with a productive cough with rusty coloured sputum, which is a common symptom of pneumonia. The chest X-ray showed lobar consolidation on the left side, indicating a specific type of pneumonia known as lobar pneumonia.

Streptococcus pneumoniae is the most likely causative organism in this scenario. This bacterium is a common cause of community-acquired pneumonia, especially in adults. It is known to cause lobar pneumonia, which is characterized by consolidation of an entire lobe of the lung.

Haemophilus influenzae is another common cause of pneumonia, but it is more commonly associated with bronchitis and exacerbations of chronic obstructive pulmonary disease (COPD). Legionella pneumophila is known to cause Legionnaires’ disease, which presents with symptoms similar to pneumonia but is usually associated with contaminated water sources.

Mycobacterium tuberculosis is the causative organism for tuberculosis, which typically presents with a chronic cough, weight loss, and night sweats. Pneumocystis jiroveci is a fungus that causes pneumonia in immunocompromised individuals, such as those with HIV/AIDS.

Overall, based on the patient’s presentation and the chest X-ray findings, Streptococcus pneumoniae is the most likely causative organism for the lobar pneumonia in this 43-year-old female patient.

The World Health Organization (WHO) has set a goal to end the AIDS epidemic by 2030 through its Fast-Track strategy. This strategy involves accelerating the scale-up of HIV prevention, treatment, and care services in order to reach key targets by 2020 and ultimately end the epidemic by 2030. This includes increasing access to HIV testing and treatment, reducing new HIV infections, and eliminating AIDS-related deaths. By focusing on key populations most affected by HIV, such as men who have sex with men, sex workers, people who inject drugs, and transgender individuals, the WHO aims to achieve these targets and ultimately end the AIDS epidemic by 2030.

Antiretroviral therapy (ART) is a crucial component of HIV treatment that helps to suppress the virus and prevent disease progression. Therefore, it is generally recommended that ART be initiated as soon as possible after an HIV diagnosis, regardless of the client’s clinical condition or symptoms.

However, there may be certain circumstances where delaying ART is considered. One such circumstance is when concerns about the client’s ability to adhere to the medication regimen outweigh the risk of HIV disease progression. Adherence to ART is essential for its effectiveness, and if a client is unable or unwilling to adhere to the prescribed regimen, it may be more beneficial to delay starting ART until the client is better able to adhere to the treatment plan.

In all other cases, including if the client prefers alternative therapies, if the client’s clinical condition is not severe, if the client is asymptomatic, or if laboratory results are available, ART should not be delayed. The benefits of starting ART early and maintaining adherence to the treatment plan far outweigh any potential risks or concerns in these situations.

During pregnancy, it is important to provide effective antiretroviral therapy (ART) to prevent mother-to-child transmission of HIV. The preferred regimen for pregnant women newly initiating ART is Tenofovir (TDF), Lamivudine (3TC), and Dolutegravir (DTG) for several reasons.

Tenofovir (TDF) is a well-tolerated and effective antiretroviral drug that is safe to use during pregnancy. Lamivudine (3TC) is also considered safe and effective for use in pregnant women. Dolutegravir (DTG) is a newer antiretroviral drug that has shown high efficacy and a good safety profile in pregnant women.

This regimen is preferred over other options such as Zidovudine (AZT) due to potential side effects and resistance issues, and Efavirenz (EFV) due to concerns about potential birth defects. Tenofovir (TDF), Lamivudine (3TC), and Dolutegravir (DTG) is considered a safe and effective option for pregnant women to help reduce the risk of mother-to-child transmission of HIV.

To assess renal insufficiency for TDF (tenofovir disoproxil fumarate) use in adults and adolescents, it is important to measure the estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) equation. This is because TDF is primarily excreted by the kidneys, and individuals with impaired renal function may be at a higher risk of developing kidney-related side effects from the medication. Monitoring eGFR levels can help healthcare providers determine if TDF is safe to use or if dosage adjustments are necessary to prevent kidney damage. Other parameters such as CD4 cell count, HBsAg, haemoglobin (Hb), and mid upper arm circumference (MUAC) may also be important for assessing overall health and treatment response, but specifically for assessing renal insufficiency related to TDF use, eGFR using the MDRD equation is the key measurement.

The 2023 ART Clinical Guidelines have introduced simplified ART provision and harmonised methods of management as a new feature. This means that the guidelines aim to make it easier for healthcare providers to prescribe and manage antiretroviral therapy (ART) for patients of all ages and conditions, including children, adolescents, adults, and pregnant women living with HIV/AIDS, TB, and other common opportunistic infections. By streamlining and standardizing the approach to ART provision and management, the guidelines seek to improve the quality of care and outcomes for patients across different groups. This new feature reflects the ongoing efforts to enhance the effectiveness and accessibility of HIV treatment and care.

Breastfeeding is recommended for infants living with HIV because breast milk provides essential nutrients and antibodies that help support the baby’s immune system and overall health. However, it is crucial that the mother is on antiretroviral therapy (ART) to reduce the risk of transmitting the virus through breast milk. By following the guidelines and ensuring the mother’s viral load is suppressed, the benefits of breastfeeding can outweigh the risks of HIV transmission. It is important for healthcare providers to educate and support mothers in making informed decisions about breastfeeding their infants while living with HIV.

Leptospirosis is a bacterial infection caused by the spirochete Leptospira. It is commonly transmitted to humans through contact with water, soil, or food contaminated with the urine of infected animals, such as rodents. Symptoms of leptospirosis can range from mild flu-like symptoms to severe complications such as kidney failure and liver damage.

In this case, the patient’s history of bathing in a river in India, along with symptoms of fever, myalgia, headache, and abdominal pain, are highly suggestive of leptospirosis. The presence of severe muscle tenderness, hypotension, and tachycardia indicate that the patient is in a state of shock and requires immediate medical attention.

The first step in managing a patient with suspected leptospirosis who is in shock is to initiate resuscitation with IV fluids to stabilize their blood pressure and improve tissue perfusion. This is crucial in preventing further complications and organ damage. IV antibiotics, such as Doxycycline or Penicillin, should also be started promptly to treat the underlying infection.

While other investigations such as abdominal and chest X-rays may be necessary to rule out other possible diagnoses, the priority in this case is to address the patient’s hemodynamic instability and initiate appropriate antibiotic therapy. Once the patient is stabilized, further diagnostic tests and management can be pursued as needed.

Indeterminate HIV-PCR results in infants can be a cause for concern as it is unclear whether the infant is truly infected with HIV or not. In such cases, it is important to take immediate action to determine the infant’s HIV status and provide appropriate care.

The recommended approach for infants with indeterminate HIV-PCR results is to repeat both the HIV-PCR and HIV rapid test urgently. This is necessary to confirm the infant’s HIV status and ensure that appropriate treatment and care can be provided if the infant is indeed infected with HIV.

Initiating antiretroviral therapy (ART) immediately may be considered if the repeat tests confirm HIV infection. Discontinuing breastfeeding may also be necessary to prevent transmission of the virus to the infant. Administering high-risk infant prophylaxis can help reduce the risk of HIV transmission in cases where the infant’s HIV status is still uncertain.

It is important not to defer further testing until the infant is older, as early diagnosis and treatment of HIV in infants is crucial for their long-term health outcomes. Therefore, repeating both the HIV-PCR and HIV rapid test urgently is the recommended approach in cases of indeterminate HIV-PCR results in infants.

Variant Creutzfeldt-Jakob disease (vCJD) is caused by prions, which are abnormal proteins that can cause normal proteins in the brain to become misfolded and form clumps. Prions are not living organisms like viruses, bacteria, parasites, or arachnids, but rather infectious proteins that can cause neurodegenerative diseases in humans and animals. In the case of vCJD, it is believed to be caused by consuming food contaminated with prions, particularly from animals infected with bovine spongiform encephalopathy (BSE), also known as mad cow disease. This makes prions the correct answer for the pathogen in variant Creutzfeldt-Jakob disease.

Prophylaxis against Pneumocystis jirovecii pneumonia is an extremely beneficial intervention for infants with HIV, especially for those not yet receiving antiretroviral therapy. The highest incidence of Pneumocystis pneumonia in children with HIV occurs during the first year of life, with cases peaking at 3 to 6 months of age. For children under age 13, the Pediatric OI Guidelines recommend the following for administering Pneumocystis pneumonia prophylaxis:

Ages 1 to 12 Months (including those who are HIV indeterminate): All children ages 1 to 12 months who have diagnosed HIV (or HIV indeterminate results) should receive Pneumocystis pneumonia prophylaxis, regardless of CD4 cell count or CD4 percentage.
Ages 1-5 Years: Children with HIV who are 1 to 5 years of age should receive Pneumocystis pneumonia prophylaxis if they have a CD4 count less than 500 cells/mm3 or their CD4 percentage is less than 15%.
Ages 6-12 Years: Children with HIV infection aged 6 to 12 years should receive Pneumocystis pneumonia prophylaxis if the CD4 count is less than 200 cells/mm3 or the CD4 percentage is less than 15%.
All infants should continue Pneumocystis pneumonia prophylaxis until age 1 year and then undergo reassessment for the need for prophylaxis. For children with HIV older who are than 1 year of age, discontinuing Pneumocystis pneumonia prophylaxis should be considered if the child has received combination antiretroviral therapy for at least 6 months and the CD4 count and percentage have been above the age-specific threshold for initiating prophylaxis for at least 3 consecutive months.

Trimethoprim-sulfamethoxazole is the preferred agent for Pneumocystis pneumonia prophylaxis for all infants and children. For those unable to take trimethoprim-sulfamethoxazole, acceptable alternatives include dapsone or atovaquone.

The most likely diagnosis for the 21-year-old man with general malaise, low-grade temperature, and painful ulceration of his mouth and gums is a Herpes simplex virus infection. This is indicated by the presence of gingivostomatitis, which is a characteristic feature of primary herpes simplex virus infection.

Herpetic gingivostomatitis is often the initial presentation during the first herpes simplex infection and is typically caused by HSV-1. It is more severe than herpes labialis (cold sores) and is the most common viral infection of the mouth. Symptoms of herpetic gingivostomatitis can include fever, anorexia, irritability, malaise, headache, submandibular lymphadenopathy, halitosis, and refusal to drink.

Other options such as Epstein Barr virus, Lichen planus, and HIV seroconversion illness are less likely in this case based on the presentation of symptoms. Epstein Barr virus infection may present with symptoms similar to infectious mononucleosis, Lichen planus typically presents with white, lacy patches in the mouth, and HIV seroconversion illness may present with a variety of symptoms but typically not with the characteristic ulceration seen in herpes simplex virus infection.

Assessing renal function before initiating TDF-containing regimens is important because TDF is primarily excreted through the kidneys. If a patient already has impaired renal function, TDF may accumulate in the body and lead to potential toxicity. By assessing renal function before starting TDF, healthcare providers can determine if the patient’s kidneys are functioning well enough to safely metabolize and excrete the drug.

The primary reason for assessing renal function before initiating TDF-containing regimens is to ensure safe use of the drug without exacerbating pre-existing renal impairment. This is important for preventing potential complications and adverse effects that may arise from TDF accumulation in the body. Monitoring renal function allows healthcare providers to adjust the dosage or consider alternative treatment options if necessary to minimize the risk of kidney-related complications.

Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) commonly used in the treatment of HIV. One of the primary concerns associated with the use of EFV is its potential to cause neuropsychiatric side effects, particularly insomnia and vivid dreams. These side effects can be quite distressing for patients and may impact their quality of life.

Insomnia is a common side effect of EFV and can lead to difficulties falling asleep or staying asleep. This can result in fatigue, irritability, and difficulty concentrating during the day. In addition, some patients may experience vivid dreams or nightmares, which can be disruptive to sleep and cause further distress.

In some cases, the neuropsychiatric side effects of EFV can be severe and may include symptoms such as depression, anxiety, hallucinations, and suicidal thoughts. It is important for healthcare providers to monitor patients closely for these side effects and to provide appropriate support and interventions as needed.

Overall, while EFV is an effective antiretroviral medication for the treatment of HIV, the potential for neuropsychiatric side effects, particularly insomnia and vivid dreams, is a significant concern that should be carefully considered when prescribing this medication.

The first viral load (VL) measurement after initiating antiretroviral therapy (ART) is crucial in monitoring the effectiveness of the treatment in suppressing the HIV virus. By taking the VL after 3 dispensing cycles, healthcare providers can assess how well the medication is working and whether the patient is responding positively to the treatment. This early check allows for any necessary adjustments to be made to the treatment plan if the viral load is not decreasing as expected. Additionally, monitoring the VL early on can help identify any potential issues or challenges that may arise in achieving viral suppression. Therefore, it is important to follow the guidelines and take the first VL measurement after 3 dispensing cycles to ensure the best possible outcomes for the patient.

The patient in this case is presenting with symptoms of vomiting, diarrhea, and blood in the stool after consuming a meal of chicken and chips. The presence of Campylobacter Jejuni in her stool culture suggests that she has contracted a Campylobacter infection, which is a common cause of foodborne illness.

In this scenario, the most appropriate therapy would be IV fluids to help rehydrate the patient and replace any lost fluids due to vomiting and diarrhea. IV fluids are essential in managing dehydration, which can be a serious complication of gastrointestinal infections.

Amoxicillin, Cefaclor, Metronidazole, and Trimethoprim are not appropriate treatments for Campylobacter infection. Erythromycin is the antibiotic of choice for treating Campylobacter infections in adults, although the use of antibiotics in these cases is still debated. Ciprofloxacin and Tetracycline may also be effective in treating Campylobacter infections.

Overall, the priority in managing this patient would be to provide supportive care with IV fluids and monitor for any signs of dehydration or worsening symptoms. Antibiotic therapy may be considered based on the severity of the infection and the patient’s overall health status.

The question presents a 16-year-old female with HIV who is experiencing blurring of vision and blind spots in her field of vision. Given her low CD4 count of 45 cells/mL, the most likely complication that has occurred is cytomegalovirus (CMV) retinitis. This condition is a common ocular manifestation of HIV infection, especially in patients with severely compromised immune systems. CMV retinitis typically occurs when the CD4 count falls below 50/μL, making this patient’s CD4 count of 45 cells/mL a significant risk factor.

CMV retinitis is characterized by inflammation of the retina, leading to symptoms such as blurring of vision and blind spots. The treatment for CMV retinitis involves systemic intravenous administration of antiviral medications such as Ganciclovir or Foscarnet. These medications help to control the viral replication and prevent further damage to the retina. Maintenance treatment with oral Ganciclovir is often necessary to prevent recurrence of the infection.

In conclusion, the most likely complication that has occurred in this patient with HIV, resulting in her ocular damage, is CMV retinitis. It is important for healthcare providers to be aware of this potential complication in HIV-infected patients with low CD4 counts, as early detection and treatment are crucial in preventing permanent vision loss.

It is important for women who opt not to be tested for HIV during prenatal visits to still have access to information and support regarding their decision. Offering ‘post-refusal’ counseling allows healthcare providers to address any concerns or misconceptions the woman may have about HIV testing, and to provide education on the importance of testing for both her own health and the health of her baby.

Providing the option for re-testing at every subsequent visit ensures that the woman has ongoing opportunities to change her mind and consent to testing if she wishes. This approach respects the woman’s autonomy while also prioritizing the health and well-being of both her and her baby.

Immediate ART initiation without testing, discontinuing prenatal care, or mandatory testing regardless of consent are not recommended approaches as they do not respect the women’s autonomy and may lead to negative outcomes for both the woman and her baby. Offering a one-time test at delivery may not provide enough time for appropriate interventions to be implemented if the woman is found to be HIV positive.

In summary, offering ‘post-refusal’ counseling and re-testing at every subsequent visit is the recommended approach for women who choose not to be tested for HIV during prenatal visits.

When a client on TLD (Tenofovir disoproxil fumarate-Lamivudine-Dolutegravir) has a viral load ≥ 1000 c/mL after at least two years on treatment, it is important to assess the situation carefully before making any changes to the regimen. Performing a resistance test is crucial in this scenario as it helps determine if the client has developed resistance to any of the components of the TLD regimen. This information is essential for clinicians to make informed decisions about the next steps in managing the client’s HIV treatment.

Switching immediately to a third-line regimen may not be necessary if the resistance test shows that the client’s virus is still susceptible to the current TLD regimen. Continuing TLD and focusing on addressing adherence issues may be a more appropriate approach in this case. If the resistance test reveals resistance to one or more components of TLD, then adding another antiretroviral drug to the current regimen or switching to a third-line regimen may be necessary.

In conclusion, performing a resistance test before making any changes to the regimen for clients on TLD with a viral load ≥ 1000 c/mL after at least two years on treatment is essential for appropriate management based on the resistance profile. This approach ensures that the client receives the most effective and personalized treatment for their HIV infection.

Neonates born to HIV-positive mothers are at risk of acquiring the virus during childbirth or through breastfeeding. To prevent mother-to-child transmission of HIV, it is crucial to provide antiretroviral therapy (ART) to these neonates as soon as possible after birth.

For neonates born to HIV-positive mothers from birth to less than 4 weeks of age and weighing ≥ 3.0 kg, the recommended ART regimen is Zidovudine (AZT) + Lamivudine (3TC) + Nevirapine (NVP). This combination of antiretroviral drugs has been shown to be effective in reducing the risk of HIV transmission from mother to child.

Zidovudine (AZT) and Lamivudine (3TC) are nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the replication of the HIV virus. Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that also helps to prevent the virus from multiplying in the body.

By starting ART early in neonates born to HIV-positive mothers, healthcare providers can significantly reduce the risk of HIV transmission and improve the long-term health outcomes of these infants. It is important for healthcare providers to closely monitor the neonates on this ART regimen and adjust the treatment as needed based on their individual health status.

Nevirapine (NVP) is an antiretroviral medication used to treat HIV/AIDS in infants. The dosing recommendation for infants aged birth to 6 weeks and weighing between 2.0 to 2.49 kg is 1 ml (10 mg) once daily. This dosage is based on the weight of the infant and is important to ensure the medication is effective and safe for the child.

The correct treatment option for this patient would be Entecavir. Entecavir is a potent antiviral medication that is recommended as a first-line treatment for chronic hepatitis B. It works by inhibiting viral replication and reducing the viral load in the body. This can help to improve liver function and reduce inflammation, ultimately slowing down the progression of liver disease.

Interferon alfa alone is not typically recommended for patients with chronic hepatitis B, as it is less effective than newer antiviral medications like Entecavir. Pegylated interferon alfa 2a and ribavirin may be used in some cases, but Entecavir is generally preferred due to its higher efficacy and better tolerability.

In this case, the patient has evidence of early fibrosis and moderate inflammation on liver biopsy, indicating that treatment is necessary to prevent further liver damage. Entecavir would be the most appropriate choice to help control the infection and improve liver health in this patient.

Lipodystrophy is a common side effect of certain antiretroviral drugs used to treat HIV, such as Efavirenz (EFV). Lipodystrophy is characterized by changes in body fat distribution, including fat loss in the face, arms, legs, and buttocks, and fat accumulation in the abdomen, back of the neck, and breasts. This can lead to metabolic abnormalities such as insulin resistance, dyslipidemia, and increased risk of cardiovascular disease.

Among the options provided, Efavirenz (EFV) is the drug commonly associated with lipodystrophy. Ritonavir (RTV) is more commonly associated with metabolic abnormalities such as dyslipidemia and insulin resistance. Nevirapine (NVP) is not typically associated with lipodystrophy, but can cause liver toxicity. Tenofovir disoproxil fumarate (TDF) is known to cause renal toxicity and bone loss, but not specifically lipodystrophy. Abacavir (ABC) is associated with hypersensitivity reactions, but not typically lipodystrophy.

It is important for healthcare providers to closely monitor patients on EFV for signs of lipodystrophy and metabolic abnormalities, and to intervene as needed to mitigate these adverse effects. This may include switching to a different antiretroviral drug or implementing lifestyle changes to manage metabolic abnormalities.

HIV testing is recommended to be offered at every routine antenatal care visit for pregnant women because early detection and treatment of HIV during pregnancy can significantly reduce the risk of mother-to-child transmission of the virus. By testing regularly throughout the pregnancy, healthcare providers can ensure that any potential cases of HIV are identified promptly and appropriate interventions can be implemented to protect both the mother and the baby. Additionally, offering HIV testing at every antenatal care visit helps to normalize the practice and reduce stigma associated with HIV testing, making it more likely that pregnant women will accept testing. This approach aligns with the World Health Organization’s recommendation for universal HIV testing in antenatal care settings.